{"id":67186,"date":"2016-07-31T12:00:15","date_gmt":"2016-07-31T16:00:15","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=67186"},"modified":"2016-07-31T07:21:09","modified_gmt":"2016-07-31T11:21:09","slug":"pdufa","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2016\/07\/31\/pdufa\/","title":{"rendered":"pdufa?&#8230;"},"content":{"rendered":"<div align=\"justify\" class=\"small\">Here are a few versions describing the <strong><font color=\"#200020\">Prescription Drug User Fee Act <\/font><\/strong>[<strong><font color=\"#200020\"><strong><font color=\"#200020\">PDUFA<\/font><\/strong><\/font><\/strong>] [1] <a target=\"_blank\" href=\"https:\/\/en.wikipedia.org\/wiki\/Prescription_Drug_User_Fee_Act\">Wikipedia<\/a> [2] <a target=\"_blank\" href=\"http:\/\/www.fda.gov\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/\">FDA<\/a> [3] <a target=\"_blank\" href=\"http:\/\/www.phrma.org\/pdufa\">P<em>h<\/em>RMA<\/a>. Essentially it&#8217;s a deal between P<em>h<\/em>RMA and the FDA. The drug manufacturers pay when they register an NDA [<font color=\"#200020\">New Drug Application<\/font>], and in return, the FDA uses the money to speed up the evaluation process. It accounts for a large chunk of the FDA budget.<\/div>\n<p align=\"justify\" class=\"small\"><em><font color=\"#200020\">PharmaGuy<\/font><\/em> is one [of many] who question the whole idea of PDUFA. Fearing that the FDA is rushing drugs through and in the process approving dangerous drugs. Last year, in a blog <a href=\"http:\/\/pharmamkting.blogspot.com\/2014\/08\/do-pdufa-fees-encourage-approval-of.html\" target=\"_blank\">Do PDUFA Fees Encourage Approval of Dangerous Drugs and\/or Undermine FDA&#8217;s Regulatory Oversight of Approved Drugs?<\/a> he cited a <em><font color=\"#200020\">Public Citizen Report<\/font><\/em> that showed that &quot;<em><font color=\"#200020\">drugs released after the 1992 enactment of the Prescription Drug User  Fee Act (PDUFA) &#8230; were more likely to be withdrawn or have a black box warning<\/font><\/em>&quot; [<a href=\"http:\/\/www.citizen.org\/pressroom\/pressroomredirect.cfm?ID=4258\" target=\"_blank\">Safety Concerns About New Drugs Revealed<\/a>]. He also reported that with PDUFA, the FDA is issuing fewer warning letters:  <\/p>\n<p align=\"center\" class=\"small\"><a href=\"http:\/\/1.bp.blogspot.com\/-Xwe2iGyRuL0\/VCrmnaWET-I\/AAAAAAAAHV0\/ma9yy_1PrfE\/s1600\/PDUFA-v-Letters-Chart.jpg\" target=\"_blank\"><\/a><a href=\"http:\/\/1.bp.blogspot.com\/-Xwe2iGyRuL0\/VCrmnaWET-I\/AAAAAAAAHV0\/ma9yy_1PrfE\/s1600\/PDUFA-v-Letters-Chart.jpg\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" width=\"350\" height=\"414\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/pguy-0.gif\" \/><\/a><\/p>\n<div align=\"justify\" class=\"small\">Now <em><font color=\"#200020\">PharmaGuy<\/font><\/em>&#8216;s back with some other indirect evidence:  <\/div>\n<blockquote>\n<div align=\"center\" class=\"big\"><a href=\"http:\/\/pharmamkting.blogspot.ca\/2016\/07\/fdas-dependence-on-user-fees.html\" target=\"_blank\">FDA&#8217;s Dependence on User Fees &amp; &quot;Institutional Corruption&quot; Blamed for Dramatic Increase in Drug Adverse Events and Deaths <\/a><\/div>\n<div align=\"center\" class=\"big\"><strong><font color=\"#000001\">Pharma Marketing Blog<\/font><\/strong><\/div>\n<div align=\"center\" class=\"middle\">by PharmaGuy <\/div>\n<div align=\"center\" class=\"middle\">July 25, 2016<\/div>\n<p align=\"justify\">An estimated 128,000 hospitalized patients die each year from Adverse  Drug Reactions [ADRs. aka Adverse Events, AEs], which matches stroke as  the 4th leading cause of hospital deaths [see <a href=\"http:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=2282014\">here<\/a>].  Deaths and serious reactions outside of hospitals would signicantly  increase the totals. This does not include deaths and hospitalizations  from over-dosing, errors, or recreational drug use. We know this because  of &nbsp;hundreds of thousands of drug &quot;Adverse Event Reports&quot; [AERs]  received by the FDA every year directly from healthcare professionals  [HCPs such as physicians, pharmacists, nurses and others], consumers  [such as patients, family members, lawyers and others], and drug  companies, which are normally required to send AERs it receives from  HCPs to the FDA. The following chart shows the trend in AERs received by the FDA from 2004 through 2015:<\/p>\n<p align=\"center\"><a target=\"_blank\" href=\"https:\/\/4.bp.blogspot.com\/-dRYrfQZT698\/V5ZScFZsEOI\/AAAAAAAAIx4\/CdavxP2J0YsnGbxCU1tOlUiQZrKmqGSxQCLcB\/s1600\/AER-TrendCharts2004-2015.jpg\"><img loading=\"lazy\" decoding=\"async\" width=\"350\" height=\"335\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/pguy-1.gif\" \/><\/a><\/p>\n<p align=\"justify\">I have analyzed data from 2003 through 2014 to look at the number of  AERs submitted by HCPs versus consumers, the number of serious adverse  events versus the number of adverse events involving death, and the  correlation between serious AEs and user fees paid to the FDA by drug  companies. I see some interesting trends in the data.<\/p>\n<p align=\"justify\">In 2014 &#8211; for the first time &#8211; more AERs were submitted by consumers than by HCPs as shown in the following two chart.<\/p>\n<p align=\"center\"><a target=\"_blank\" href=\"https:\/\/1.bp.blogspot.com\/-jhyKSU98n5k\/V5ZcOUaBrFI\/AAAAAAAAIyI\/2RzBfQRumpcm7D26RotFMKX5YgBoZY6ygCLcB\/s1600\/AER-HCP-v-Consumer-Trend.jpg\"><img loading=\"lazy\" decoding=\"async\" width=\"350\" height=\"575\" border=\"0\" align=\"middle\" src=\"http:\/\/1boringoldman.com\/images\/pguy-2.gif\" \/><\/a><\/p>\n<p align=\"justify\">Not only is the FDA receiving more AERs every year, the number of  serious AEs and AEs involving death are also increasing rather  dramatically as shown in the following chart.<\/p>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" align=\"center\">\n<tr>\n<td><a target=\"_blank\" href=\"https:\/\/3.bp.blogspot.com\/-1A-hTAztU70\/V5ZouzY5vFI\/AAAAAAAAIyY\/PGBK9HeAE-YojQ-BLHYhDb8p_oLH3HQCgCLcB\/s1600\/Serious-and-Death-AER-trendcharts.jpg\"><img loading=\"lazy\" decoding=\"async\" width=\"350\" height=\"188\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/pguy-3.gif\" \/><\/a><\/td>\n<\/tr>\n<tr>\n<td align=\"center\">Click on image for an enlarged view.<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">The Harvard Edmond J. Safra Center for Ethics reports that a forthcoming article in the <em>Journal of Law, Medicine and Ethics<\/em> [&quot;<a href=\"http:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=2282014\" target=\"_blank\">Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs<\/a>&quot;]  will present &quot;systematic, quantitative evidence that since the industry  started making large contributions to the FDA for reviewing its drugs,  as it makes large contributions to Congressmen who have promoted this  substitution for publicly funded regulation, the FDA has sped up the  review process with the result that drugs approved are significantly  more likely to cause serious harm, hospitalizations, and deaths. New FDA  policies are likely to increase the epidemic of harms&quot; [read &quot;<a href=\"http:\/\/ethics.harvard.edu\/blog\/risky-drugs-why-fda-cannot-be-trusted\" target=\"_blank\">Risky Drugs: Why The FDA Cannot Be Trusted<\/a>&quot;].<\/p>\n<p align=\"justify\">The authors of the JLME paper contend that &quot;in return for paying user  fees, companies required the FDA to guarantee that it would review  priority applications within six months and standard applications within  12 months of submission. Shortened review times led to substantial  increases in serious harms.&quot; I thought this was an interesting because I  have been following the negative correlation between the rise in user  fees and the decrease in FDA warning letters, which may encourage  approval of dangerous drugs by the FDA [see the data charted in this  post: &quot;<a href=\"http:\/\/pharmamkting.blogspot.com\/2014\/08\/do-pdufa-fees-encourage-approval-of.html\" target=\"_blank\">Do PDUFA Fees Encourage Approval of Dangerous Drugs and\/or Undermine FDA&#8217;s Regulatory Oversight of Approved Drugs?<\/a>&quot;]. <\/p>\n<p align=\"justify\">So, I decided to plot the number of AERs involving serious side effects  along with the rise in user fees collected by the FDA from pharma  companies and came up with the following chart.<\/p>\n<p align=\"center\"> <a target=\"_blank\" href=\"https:\/\/4.bp.blogspot.com\/-2aP8eTZMVRI\/V5ZxxsjyWfI\/AAAAAAAAIyo\/lMmiRga_RWMqkUUQ7WtxP__VKffLp911wCLcB\/s1600\/Serious-AER-v-PDUFA.jpg\"><img decoding=\"async\" width=\"350\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/pguy-4.gif\" \/><\/a><\/p>\n<div align=\"justify\">  Of course, this does not prove a correlation between PDUFA fees and  serious AERs, but it does lend support to the &quot;institutional corruption&quot;  argument posit in the above article. <\/div>\n<\/blockquote>\n<p align=\"justify\" class=\"small\">PDUFA is approved every 5 years, and comes up for renewal when it expires in September 2017. The current proposal aims to lower the rate of fee escalation for the next cycle [<a href=\"http:\/\/www.thepharmaletter.com\/article\/fda-pdufa-vi-goals-expected-to-slow-rate-of-user-fee-increases\" target=\"_blank\">FDA PDUFA VI &ldquo;goals&rdquo; expected to slow rate of user fee increases<\/a>]. I&#8217;ll have to admit total ignorance about PDUFA, though it does seem a very odd compromise to have reached &#8211; the FDA earning it&#8217;s funding from PHARMA by fast tracking approval? <font color=\"#200020\">Since the fees are ultimately paid by sick people buying the drugs, it appears to me that they&#8217;re being taxed [without representation] to pay for something that may well be to their detriment.<\/font> I can see why <em><font color=\"#200020\">PharmaGuy<\/font><\/em> questions PDUFA and its impact.<\/p>\n<div align=\"justify\" class=\"small\"><strong><em><font color=\"#200020\">Note to Self<\/font><\/em><\/strong>: When you get back from vacation, look into the <strong><font color=\"#200020\">Prescription Drug User Fee Act<\/font><\/strong>&#8230;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Here are a few versions describing the Prescription Drug User Fee Act [PDUFA] [1] Wikipedia [2] FDA [3] PhRMA. Essentially it&#8217;s a deal between PhRMA and the FDA. The drug manufacturers pay when they register an NDA [New Drug Application], and in return, the FDA uses the money to speed up the evaluation process. It [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-67186","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/67186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=67186"}],"version-history":[{"count":26,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/67186\/revisions"}],"predecessor-version":[{"id":67204,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/67186\/revisions\/67204"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=67186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=67186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=67186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}